Bicara Therapeutics Inc. Capital Expenditures
Bicara Therapeutics Inc. (BCAX) reported Capital Expenditures of $120.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-11
- Bicara Therapeutics Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $60.00K.
- Bicara Therapeutics Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $60.00K.
- Bicara Therapeutics Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $238.00K, a 495.00% increase year-over-year.
- Bicara Therapeutics Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $42.00K, a 425.00% increase year-over-year.
- Bicara Therapeutics Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $280.00K, a 294.37% increase from fiscal 2024.
- Bicara Therapeutics Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $71.00K, a 87.88% decline from fiscal 2023.
- Bicara Therapeutics Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $586.00K.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $60.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $120.00K 10-Q · filed 2026-08-11 | $358.00K derived: sum of 3 quarters · filed 2026-08-11 | $400.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | $60.00K 10-Q · filed 2026-05-11 | $298.00K derived: sum of 2 quarters · filed 2026-05-11 | $340.00K derived: sum of 3 quarters · filed 2026-05-11 | $340.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | $238.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $280.00K derived: sum of 2 quarters · filed 2026-03-30 | $280.00K derived: sum of 3 quarters · filed 2026-08-11 | $280.00K 10-K · filed 2026-03-30 |
| 2025-09-30 | $42.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $42.00K derived: sum of 2 quarters · filed 2026-08-11 | $42.00K 10-Q · filed 2025-11-10 | $82.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $0.00 10-Q · filed 2026-08-11 | $40.00K derived: sum of 3 quarters · filed 2026-08-11 | $48.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-11 | $40.00K derived: sum of 2 quarters · filed 2026-05-11 | $48.00K derived: sum of 3 quarters · filed 2026-05-11 | $67.00K derived: sum of 4 quarters · filed 2026-05-11 |
| 2024-12-31 | $40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $48.00K derived: sum of 2 quarters · filed 2026-03-30 | $67.00K derived: sum of 3 quarters · filed 2026-03-30 | $71.00K 10-K · filed 2026-03-30 |
| 2024-09-30 | $8.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $27.00K derived: sum of 2 quarters · filed 2025-11-10 | $31.00K 10-Q · filed 2025-11-10 | $467.00K derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $19.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $23.00K 10-Q · filed 2025-08-12 | $459.00K derived: sum of 3 quarters · filed 2025-08-12 | |
| 2024-03-31 | $4.00K 10-Q · filed 2025-05-13 | $440.00K derived: sum of 2 quarters · filed 2025-05-13 | ||
| 2023-12-31 | $436.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $586.00K 10-K · filed 2025-03-27 | ||
| 2023-09-30 | $150.00K 10-Q · filed 2024-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B |